Wednesday, March 9, 2011
Plexxikon Inc., of Berkeley, Calif., treated the first patient in a Phase II study of PLX3397, a selective inhibitor designed to down-modulate macrophages and mast cells, in Hodgkin lymphoma. About 30 patients with relapsed or refractory disease are expected to be enrolled. Objectives of the study include assessing the efficacy of oral PLX3397 as measured by overall response rate, as well as the duration of response, the disease control rate, progression-free survival, response biomarkers and overall safety.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.